HOME >> BIOLOGY >> NEWS
Kaposi sarcoma arises independently from multiple cells

Kaposi sarcoma is unique among cancers because most tumors grow from a small number of different cells, whereas nearly all other cancers arise from a single cell, according to a study published online July 10 in the Journal of the National Cancer Institute.

Kaposi sarcoma, which is often associated with AIDS, primarily affects the skin. But as the disease progresses, it can move to the lymph nodes and internal organs as well.

Renan Duprez, Ph.D., of the Institut Pasteur in Paris and colleagues performed the largest study to date on the origins of advanced Kaposi sarcoma. Biopsies from 98 Kaposi sarcoma patients were analyzed using molecular diagnostic techniques to compare the viral DNA of the tumors, which often contain human herpesvirus 8.

The researchers found evidence that nearly 80% of the tumors arose independently from multiple cells. They concluded that few Kaposi sarcoma tumors originate from a single cell and that Kaposi sarcoma, especially in its advanced form, is not true metastatic cancer.

In an accompanying editorial, Parkash Gill, M.D., of Norris Cancer Hospital and Research Institute in Los Angeles recommends what should come next in Kaposi sarcoma research.

With some resolution as to the clonal nature of [Kaposi sarcoma] of the skin and lymph node, similar analysis remains to be done for visceral [Kaposi sarcoma], which can be more invasive leading at times to catastrophic organ dysfunction and even death. It is also not known if the clonal [Kaposi sarcoma] lesions identified in this study were more aggressive and less likely to respond to therapy, Gill writes.


'"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
10-Jul-2007


Page: 1

Related biology news :

1. Marijuana component opens the door for virus that causes Kaposis sarcoma
2. CTRC enrolls first patients in novel phase II study for sarcoma -- living virus destroys cancer cell
3. Co-operation between GSF and clinic improves outlook for sarcoma patients
4. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
5. Mouse model advances understanding of synovial sarcoma
6. Progress against sarcoma
7. Genetic analyis for personalizing of treatment of lung and colon cancer, certain sarcomas
8. Insights into osteosarcoma in cats and dogs may improve palliative care
9. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
10. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
11. Research teams uncover risk genes for multiple sclerosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... ... 17, 2020 , ... Commercial launch readiness is a critical stage in a ... cure or vaccine, the global economic downturn will only increase price pressures overall for ... and capturing full value from every product launch is critical. However, history shows that ...
(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics ... recognition and multiple awards for not only the products and treatments developed, but ... and Vivace® Microneedle RF. All the brands built by ABM have received several ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the ... clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... ... August 29, 2020 , ... ... Nutrition manufacturing capability in Wuxi, China. The new plant operation will provide the ... and advanced technology. , “This facility will improve the flexibility of our ...
(Date:8/15/2020)... ... August 13, 2020 , ... Inc. magazine today revealed ... prestigious ranking of the nation’s fastest-growing private companies. The list represents a unique ... independent small businesses. Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many other well-known ...
(Date:8/12/2020)... ... August 11, 2020 , ... Modality ... for free its new white paper – Simulated Transport Methodologies. Regulatory expectations ... biologics licensing application (BLA). In response, Modality Solutions shares an explanation of ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a ... has closed on the purchase of greenfield for a new, expanded manufacturing facility. ... over 21 acres in the initial acquisition, with an option to purchase an ...
Breaking Biology Technology:
Cached News: